EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Raphin‐1 mediates the survival and sensitivity to radiation of pediatric‐type diffuse high‐grade glioma via phosphorylated eukaryotic initiation factor 2α‐dependent and ‐independent processes

Karin Eytan iD, Moshe Leitner, Amos Toren, Shoshana Paglin, Michal Yalon

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.70081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Karin Eytan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel. Hauptthemen laut MEDLINE: Eukaryotic Initiation Factor-2, Glioma, Radiation Tolerance, Brain Neoplasms. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The primary treatment for fatal pediatric‐type diffuse high‐grade glioma (PED‐DHGG) which harbor the H3K27M or H3G34R/V mutation is radiation, but it provides only short‐term relief. Inhibitors of phosphorylated eIF2α (PeIF2α) phosphatase—namely raphin‐1 and salubrinal—decrease survival of PED‐DHGG cell lines and sensitize them to radiation. However, although both drugs increase PeIF2α, they have different effects on common targets and different targets altogether. Here, we aimed to identify PeIF2α‐phosphatase‐dependent and PeIF2α‐phosphatase‐independent molecular targets. Raphin‐1 but not salubrinal, decreased the level of BiP and CReP and increased that of DR5, in an ISRIB‐independent manner. Raphin‐1 induced similar changes in MEF S51A cells and in irradiated PED‐DHGG, suggesting a PeIF2α‐independent contribution to raphin‐1's radiosensitizing effect. Importantly, while the expression of [S51D] eIF2α decreased the survival of PED‐DHGG and both raphin‐1 and salubrinal decreased the survival of MEF WT cells, only raphin‐1 decreased the survival of mutant MEF S51A cells. Our results suggest that the sensitivity of PED‐DHGG to raphin‐1 is mediated by both PeIF2α‐dependent and PeIF2α‐independent processes. Elucidating these processes could reveal targets for the development of drugs to overcome radiotherapy resistance of PED‐DHGG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eukaryotic Initiation Factor-2GliomaRadiation ToleranceBrain NeoplasmsHumansPhosphorylationCell Line, TumorCell SurvivalCinnamatesThioureaAnimalsMiceChildNeoplasm GradingProtein Phosphatase 1

Stichwörter der Autor:innen

GRP78/BiPeIF2α phosphorylationpediatric‐type diffuse high‐grade gliomaradiationraphin‐1salubrinal

Substanzen

Eukaryotic Initiation Factor-2salubrinalCinnamatesThioureaPPP1R15A protein, humanProtein Phosphatase 1

Autor:innen und Institutionen

  • Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel.
  • Sackler School of Medicine, Tel Aviv University, Israel.
  • The Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Ramat Gan, Israel.

ORCID-Profile: Karin Eytan

Zitieren

APA

Eytan, K., Leitner, M., Toren, A., Paglin, S., & Yalon, M. (2025). Raphin‐1 mediates the survival and sensitivity to radiation of pediatric‐type diffuse high‐grade glioma via phosphorylated eukaryotic initiation factor 2α‐dependent and ‐independent processes. Molecular Oncology. https://doi.org/10.1002/1878-0261.70081

Vancouver

Eytan K, Leitner M, Toren A, Paglin S, Yalon M. Raphin‐1 mediates the survival and sensitivity to radiation of pediatric‐type diffuse high‐grade glioma via phosphorylated eukaryotic initiation factor 2α‐dependent and ‐independent processes. Molecular Oncology. 2025. doi:10.1002/1878-0261.70081

BibTeX
@article{Eytan2025,
  author = {Eytan, Karin and Leitner, Moshe and Toren, Amos and Paglin, Shoshana and Yalon, Michal},
  title = {Raphin‐1 mediates the survival and sensitivity to radiation of pediatric‐type diffuse high‐grade glioma via phosphorylated eukaryotic initiation factor 2α‐dependent and ‐independent processes},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.70081}
}
Kostenlos starten →